NASDAQ:IMMU
Delisted
Immunomedics Stock News
$87.86
+0 (+0%)
At Close: May 27, 2022
3 ETFs To Play Gilead's $21B Immunomedics Takeover
10:26am, Monday, 14'th Sep 2020
Biotechnology mergers and acquisitions appear to be back in a big way with news that Gilead Sciences is acquiring Immunomedics for $21 billion. That's a...
Vaccine hopes and M&A action power European stocks and U.S. equity futures
07:54am, Monday, 14'th Sep 2020
European stocks and U.S. equity futures are climbing as investors get optimistic over vaccine possibilities to fight the COVID-19 pandemic.
Wall Street Breakfast: Merger Monday
07:11am, Monday, 14'th Sep 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Gilead Reaches Deal to Buy Immunomedics for $21 Billion -- 5th Update | MarketScreener
12:47am, Monday, 14'th Sep 2020
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Immunomedics, Inc. (NASDAQ: IMMU) to Gilead Sciences, Inc. f
Pfizer CEO Says Its Coronavirus Drug Will Be Ready by End of 2020
08:59pm, Sunday, 13'th Sep 2020
Here’s what you need to know to navigate the markets today.
Gilead reaches $21 billion deal for Immunomedics
08:30pm, Sunday, 13'th Sep 2020
Gilead Sciences Inc. will pay $21 billion to buy biotech Immunomedics Inc. and its prized breast-cancer drug, the company said Sunday, a sign of the value of...
Gilead’s $20 Billion Gamble
08:21pm, Sunday, 13'th Sep 2020
A big premium for cancer drug company Immunomedics could pay off, but shareholders of slumping Gilead might be in no rush to act that way.
Gilead Reaches Deal to Buy Immunomedics for $21 Billion--4th Update | MarketScreener
08:15pm, Sunday, 13'th Sep 2020Gilead to buy cancer drugmaker Immunomedics in $21 billion deal
07:38pm, Sunday, 13'th Sep 2020
The deal will provide Gilead access to Immunomedics' cancer treatment drug called Trodelvy, an FDA-approved treatment for metastatic triple-negative breast cancer.
Pfizer CEO Says Its Coronavirus Drug Will Be Ready by End of 2020
04:56pm, Sunday, 13'th Sep 2020
Here’s what you need to know to navigate the markets today.
Gilead nears deal to buy Immunomedics for more than $20 billion
03:39am, Sunday, 13'th Sep 2020
Biotech drugmaker has a market value of roughly $10 billion
Gilead Sciences to Acquire Immunomedics
12:00am, Sunday, 13'th Sep 2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced today that the companies have entered into a definitive agreement pursu
Gilead near deal to buy Immunomedics for more than $20 billion
08:01pm, Saturday, 12'th Sep 2020
Gilead Sciences Inc. is nearing a deal to buy biotech Immunomedics Inc. and its prized breast-cancer drug for more than $20 billion.
